DE211894T1 - Fsh. - Google Patents

Fsh.

Info

Publication number
DE211894T1
DE211894T1 DE198686901246T DE86901246T DE211894T1 DE 211894 T1 DE211894 T1 DE 211894T1 DE 198686901246 T DE198686901246 T DE 198686901246T DE 86901246 T DE86901246 T DE 86901246T DE 211894 T1 DE211894 T1 DE 211894T1
Authority
DE
Germany
Prior art keywords
fsh
cell
expression vector
subunit
beta subunit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE198686901246T
Other languages
English (en)
Inventor
Nancy Wellesley Mass. Hsiung
Vemuri B. Framingham Mass. Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Research Systems ARS Holding NV
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24797972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE211894(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Publication of DE211894T1 publication Critical patent/DE211894T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (14)

EP 86 90 1246.8 . Reddy, Hsiung, Beck, U 2 &Iacgr; &Iacgr; O 3 PATENTANSPRÜCHE (Deutsche Übersetzung nach Regel 51(6) EPÜ)
1. Biologisch aktives, heterodimeres, menschliches ■FSH, umfassend eine Alpha-Untereinheit und eine Beta-Untereinheit, wobei beide Untereinheiten durch eine Zelle synthetisiert werden, die einen Expressions-Vektor enthält-, der heterologe DNA zur Codierung der Untereinheiten beinhaltet.
2. Beta-Untereinheit von menschlichem FSH, synthetisiert durch eine Zelle, die einen Expressions-Vektor umfaßt, der heterologe DNA zur Codierung der Beta-Untereinheit des FSH enthält.
3. Zelle, die einen Expressions-Vektor beinhaltet, wobei die Zelle imstande ist, die Beta-Untereinheit von menschlichem FSH zu produzieren, und die Beta-Untereinheit des FSH durch den Expressions-Vektor codiert ist.
4. Zelle nach Anspruch 3, die weiters einen zweiten Expressions-Vektor zur Codierung der Alpha-Untereinheit des FSH umfaßt.
5. Zelle nach Anspruch 3, wobei diese Zelle eine Säugetierzelle ist.
6. Zelle nach Anspruch 3, wobei der Vektor mindestens 69% des Transformationsbereichs des Rinder-' papillomavirusgenoms enthält.
7. Zelle nach Anspruch 5, wobei die Zelle eine Mauszelle ist.
8. Expressions-Vektor nach Anspruch 3, wobei der Expressionsvektor Plasmid enthält.
9. Expressions-Vektor, der die Beta-Untereinheit des menschlichen FSH codiert.
10. Vektor nach Anspruch 9, mit der NRRL-Zugriffsnuiraner B-15923.
11. Verfahren zur Herstellung der Beta-Untereinheit von menschlichem FSH, welches Kultivieren von Wirtszellen umfaßt, die einen Expressions-Vektor zur Codierung der Beta-Untereinheit von FSH beinhalten.
12. Verfahren zur Herstellung von biologisch aktivem, heterodimsren,· menschlichen FSH, das Kultivieren von SKugetierzellen umfaßt, die einen ersten Expressions-Vektor zur Codierung mindestens einer Untereinheit des FSH enthalten.
13. Verfahren nach Anspruch 12, wobei die erste Untereinheit des FSH durch den ersten Expressions-Vektor codiert wird, und die zweite Untereinheit des FSH durch einen zweiten Expressions-Vektor, der in der Wirtszelle enthalten ist, codiert wird.
14. Verfahren nach Anspruch 12, wobei beide Untereinheiten des FSH durch den ersten Expressions-Vektor codiert werden.
DE198686901246T 1985-01-30 1986-01-30 Fsh. Pending DE211894T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/696,647 US4923805A (en) 1983-11-02 1985-01-30 Fsh
PCT/US1986/000223 WO1986004589A1 (en) 1985-01-30 1986-01-30 Fsh

Publications (1)

Publication Number Publication Date
DE211894T1 true DE211894T1 (de) 1991-06-13

Family

ID=24797972

Family Applications (3)

Application Number Title Priority Date Filing Date
DE198686901246T Pending DE211894T1 (de) 1985-01-30 1986-01-30 Fsh.
DE19675006C Active DE19675006I2 (de) 1985-01-30 1986-01-30 Fsh.
DE8686901246T Expired - Lifetime DE3688109T2 (de) 1985-01-30 1986-01-30 Fsh.

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE19675006C Active DE19675006I2 (de) 1985-01-30 1986-01-30 Fsh.
DE8686901246T Expired - Lifetime DE3688109T2 (de) 1985-01-30 1986-01-30 Fsh.

Country Status (12)

Country Link
US (1) US4923805A (de)
EP (2) EP0521586B1 (de)
JP (5) JPH0724584B2 (de)
KR (1) KR910002692B1 (de)
AT (1) ATE87317T1 (de)
DE (3) DE211894T1 (de)
DK (2) DK171601B1 (de)
HK (1) HK143295A (de)
LU (1) LU88738I2 (de)
MX (1) MX9203681A (de)
NL (1) NL960004I2 (de)
WO (1) WO1986004589A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455282B1 (en) 1983-11-02 2002-09-24 Genzyme Corporation Cells, vectors and methods for producing biologically active TSH
US5156957A (en) * 1983-11-02 1992-10-20 Genzyme Corporation Follicle stimulating hormone
US5639639A (en) * 1983-11-02 1997-06-17 Genzyme Corporation Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
US4921808A (en) * 1986-06-25 1990-05-01 The Albany Medical College Of Union University Method for determining follicle stimulating hormone
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
IT1206302B (it) * 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
EP0453482A4 (en) 1989-01-11 1992-07-22 Us Health Biologically active synthetic thyrotropin and cloned gene for producing same
US6225449B1 (en) * 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
ATE148171T1 (de) * 1989-02-21 1997-02-15 Univ Washington Modifizierte formen von fortpflanzungshormonen
US5338835A (en) * 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
US5087615A (en) * 1989-03-17 1992-02-11 Applied Research Systems Ars Holding N.V. Novel method of ovulation induction in humans
EP0404458A3 (de) * 1989-06-19 1992-03-04 Bunge (Australia) Proprietary Limited Follikelstimulierendes Schafhormon
US5240832A (en) * 1989-06-20 1993-08-31 Genzyme Corporation Heteropolymeric protein production methods
US20080139474A1 (en) * 1991-11-04 2008-06-12 David Israel Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
DE69233022T2 (de) * 1991-11-04 2004-02-12 Genetics Institute, LLC, Cambridge Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
US6291206B1 (en) * 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US6737515B2 (en) 1993-11-19 2004-05-18 Washington University Follicle stimulating hormone-glycosylation analogs
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US6238890B1 (en) * 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US6727224B1 (en) * 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
JP2002541213A (ja) 1999-04-13 2002-12-03 インヘール セラピューティック システムズ， インコーポレイテッド 不妊症の処置のための乾燥粉末処方物の肺投与
ATE271886T1 (de) 1999-10-15 2004-08-15 Inst Genetics Llc Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US20030082233A1 (en) * 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
WO2002099037A2 (en) * 2001-06-01 2002-12-12 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
EP2042196B1 (de) 2001-10-10 2016-07-13 ratiopharm GmbH Neumodellierung und Glykokonjugation von Granulozyten-Kolonie stimulierender Faktor (G-CSF)
NZ535008A (en) * 2002-02-08 2005-09-30 Alkermes Inc Polymer-based compositions for sustained release
TW200638946A (en) * 2002-05-17 2006-11-16 Wyeth Corp Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
NZ542549A (en) * 2003-03-04 2008-11-28 Aspenbio Pharma Inc Methods and kits for maintaining pregnancy, treating follicular cysts, and synchronizing ovulation using single-chain luteinizing hormone
NZ542586A (en) 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
UA88879C2 (en) * 2003-09-02 2009-12-10 Эплайд Рисерч Системз Эрс Холдинг Н.В. Fsh glycosylation mutant
DE602004005477T2 (de) * 2003-09-12 2007-12-13 Wyeth Injizierbare feste Calciumphosphat-Stäbe zur Abgabe von osteogenen Proteinen
KR100533794B1 (ko) * 2003-10-02 2005-12-07 주식회사 프로젠 인간 난포자극 호르몬을 대량으로 생산하는 방법
KR100587535B1 (ko) * 2004-02-04 2006-06-08 충남대학교산학협력단 재조합 ｈＦＳＨ 유전자 및 이를 내장하는 발현용 벡터
US20060110423A1 (en) * 2004-04-15 2006-05-25 Wright Steven G Polymer-based sustained release device
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
PL2409707T3 (pl) 2004-04-15 2015-08-31 Amylin Pharmaceuticals Llc Urządzenie o przedłużonym uwalnianiu na bazie polimeru
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
US20100069387A1 (en) 2005-09-07 2010-03-18 Palmer Stephen S IKK Inhibitors for the Treatment of Endometriosis
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
UA103598C2 (uk) 2007-06-28 2013-11-11 Биодженерикс Аг Клон клітин, що продукують fsh
EP2412385A1 (de) 2008-02-08 2012-02-01 BioGeneriX AG Flüssige Formulierung von FSH
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
JP2009273427A (ja) 2008-05-16 2009-11-26 Jcr Pharmaceuticals Co Ltd 組換え体ヒトｆｓｈの製造方法
KR101761168B1 (ko) 2009-04-01 2017-07-25 바이오제너릭스 게엠베하 재조합 ｆｓｈ 정제 방법
MX378797B (es) 2009-09-28 2025-03-10 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
EP2325194A1 (de) 2009-11-24 2011-05-25 Glycotope GmbH Verfahren zur Reinigung von Glykoproteinen
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN103509121B (zh) 2012-11-22 2015-01-28 苏州康宁杰瑞生物科技有限公司 一种fsh融合蛋白及其制备方法和用途
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468464A (en) * 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
JPS586475B2 (ja) 1980-08-23 1983-02-04 株式会社 林原生物化学研究所 ヒト絨毛性性腺刺激ホルモンの製造方法
JPS585671B2 (ja) * 1980-08-27 1983-02-01 株式会社 林原生物化学研究所 ヒト卵胞刺激ホルモンの製造方法
US4419446A (en) * 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
ATE169334T1 (de) * 1983-11-02 1998-08-15 Applied Research Systems Herstellung heterodimirer menschlicher fruchtbarkeitshormone
DE3520404C2 (de) * 1984-06-08 1994-06-16 Genzyme Corp Schweine-ß-FSH
WO1986000923A1 (en) * 1984-07-31 1986-02-13 Integrated Genetics, Inc. Yeast cloning vehicles

Also Published As

Publication number Publication date
JPH09173064A (ja) 1997-07-08
JPS63500212A (ja) 1988-01-28
DE3688109T2 (de) 1993-07-15
JPH07255492A (ja) 1995-10-09
JPH06253884A (ja) 1994-09-13
JPH0829106B2 (ja) 1996-03-27
WO1986004589A1 (en) 1986-08-14
DE19675006I2 (de) 2008-06-12
EP0211894A1 (de) 1987-03-04
ATE87317T1 (de) 1993-04-15
LU88738I2 (fr) 1996-08-23
JPH0724584B2 (ja) 1995-03-22
EP0211894A4 (de) 1987-10-12
EP0211894B1 (de) 1993-03-24
DK171601B1 (da) 1997-02-17
JP2683563B2 (ja) 1997-12-03
EP0521586A1 (de) 1993-01-07
NL960004I1 (nl) 1996-09-02
DK463586A (da) 1986-09-29
DK172625B1 (da) 1999-03-15
KR910002692B1 (ko) 1991-05-03
EP0521586B1 (de) 1999-06-23
KR870700074A (ko) 1987-02-28
JP2757982B2 (ja) 1998-05-25
DE3688109D1 (en) 1993-04-29
DK463586D0 (da) 1986-09-29
NL960004I2 (nl) 1997-04-01
HK143295A (en) 1995-09-15
JP2559196B2 (ja) 1996-12-04
DK144695A (da) 1995-12-20
US4923805A (en) 1990-05-08
MX9203681A (es) 1992-09-01
JPH07241194A (ja) 1995-09-19

Similar Documents

Publication Publication Date Title
ATE45382T1 (de) Biosynthetisch hergestellter humannervenwachstumsfaktor, verfahren zu seiner herstellung, diesen faktor enthaltende zusammensetzungen, diesen faktor codierende dna- sequenz, vektoren, die diese sequenz enthalten und dadurch transformierte wirtszellen.
FR2681786B1 (de)
ATE5675T1 (de) Glasartiges alkalikationleitendes material, verfahren zu seiner herstellung und eine dieses material verwendende elektrochemische zelle.
KR870700074A (ko) Fsh
MD1639C2 (ro) ADN sau fragmentele lui ce codifică eritropoietina umană, vectori, celule-gazdă sau linii celulare, ADNc sau fragmentele lui ce codifică eritropoietina umană, eritropoietină recombinantă umană, procedee de obţinere a eritropoietinei umane şi eritropoietinei recombinante umane, compoziţie farmaceutică şi procedeu de obţinere a ei
AU4880093A (en) Retrovirus from the HIV group and its use
GB2286397C (en) Human neuronal nicotinic acetylcholine receptor compositions and methods of applying same
PT85193A (en) Human erythropoietin gene high level expression in stably transfected mammalian cells
DD301731A9 (de) T7 dna polymerase
PT2210947E (pt) Método para produção de proteínas segregadas
GR3007092T3 (de)
DE3884776T3 (de) Durch "site-directed" Mutagenese modifzierte Glukoprotein-Hormone und Verfahren zu deren Verwendung.
ATE113272T1 (de) Verfahren zur stabilisierung einer festen pharmazeutischen zubereitungsform von cyclischen aminosäuren.
EP0366016A3 (en) Endothelin dna and use thereof
NZ334568A (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
PT90697A (pt) Processo para a transformacao de uma celula hospedeira com um vector recombinante
CA2298412A1 (en) Identification of human cell lines for the production of human proteins by endogenous gene activation
EP0388223B1 (de) Neue Methode zur Induzierung der Ovulation beim Menschen
KR100245250B1 (en) Human follicle stimulating hormone receptor
DE3750348D1 (de) Verfahren zur Herstellung von Peptiden, dazu zu verwendendes rekombinantes Plasmid und mit diesem Plasmid transformierte Myelomzellen.
GR3020790T3 (en) Achromobacter protease I gene and gene product thereof
AU1090688A (en) Synthetic porcine growth hormone
FR2556365B1 (fr) Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g
DE3576081D1 (de) Spezifisches polypeptid produzierende hybridzellinien, erhaeltlich aus primaerzellen, die spontan faehig sind zur expres sion dieses polypeptids oder eines aehnlichen polypeptids, verfahren zum erhalten dieser hybridzellen und deren verwendung zur herstellung dieses polypeptids.
CA2145064A1 (en) Improvements in or relating to immune response modification